Some clinicians have recommended synthetic lethality with poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors for patients with a subtype of kidney cancer, including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient RCC, and renal medullary carcinoma (RMC), which are affected by genomic instability. ...